| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7910132 | SENTYNL THERAPS INC | Pharmaceutical composition for the treatment of acute disorders |
Sep, 2019
(4 years ago) | |
| US6761910 | SENTYNL THERAPS INC | Pharmaceutical composition for the treatment of acute disorders |
Sep, 2019
(4 years ago) | |
| US6759059 | SENTYNL THERAPS INC | Fentanyl composition for the treatment of acute pain |
Sep, 2019
(4 years ago) | |
Abstral is owned by Sentynl Theraps Inc.
Abstral contains Fentanyl Citrate.
Abstral has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Abstral are:
- US7910132
- US6761910
- US6759059
Abstral was authorised for market use on 07 January, 2011.
Abstral is available in tablet;sublingual dosage forms.
Abstral can be used as management of breakthrough pain in patients with cancer.
The generics of Abstral are possible to be released after 24 September, 2019.
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 07 January, 2011
Treatment: Management of breakthrough pain in patients with cancer
Dosage: TABLET;SUBLINGUAL
How can I launch a generic of ABSTRAL before it's drug patent expiration?
More Information on Dosage
ABSTRAL family patents
